Sarepta Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€2.12B - Cost of goods sold
€447.76M - Gross profit
€1.66B - SG&A expenses
€473.87M - R&D expenses
€1.20B - EBITDA
€37.51M - D&A
€41.78M - EBIT
-€794.95K - Interest expenses
€16.31M - EBT
-€20.58M - Tax expenses
€28.85M - Net income
-€49.43M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€594.92M - Changes in working capital
€213.23M - Operating cash flow
-€256.53M - Capex
€120.09M - Other investing cash flow
-€220.27M - Net investing cash flow
€320.99M - Total cash dividends paid
€0.00 - Issuance of common stock
-€40.83M - Debt repayment
€0.00 - Other financing cash flow
€65.18M - Net financing cash flow
€43.84M - Foreign exchange effects
€0.00 - Net change in cash
€121.59M - Cash at end of period
€448.80M - Free cash flow
-€136.44M
Balance sheet
- Cash and cash equivalents
€435.52M - Cash and short-term investments
€682.48M - Total receivables
€519.95M - Inventory
€847.86M - Other current assets
€215.98M - Total current assets
€2.27B - Property, plant & equipment
€439.18M - Goodwill
€0.00 - Intangible assets
€26.03M - Long-term investments
€209.57M - Other non-current assets
€197.63M - Total non-current assets
€872.42M - Total assets
€3.14B - Accounts payable
€116.60M - Short-term debt
€0.00 - Other current liabilities
€330.79M - Total current liabilities
€784.67M - Long-term debt
€1.15B - Deferred tax liabilities
€0.00 - Other non-current liabilities
€41.46M - Total non-current liabilities
€1.20B - Total liabilities
€1.98B - Common stock
€8.53K - Retained earnings
-€3.81B - Other equity
-€43.50K - Total equity
€1.16B - Total liabilities and shareholders' equity
€3.14B
Company information
- Market capitalization
€1.43B - Employees
1.4K - Enterprise Value
€4.82B
Company ratios
- Gross margin
-
78.4% Much better than peer group: -7.4% - EBITDA margin
-
1.8% Much better than peer group: -5,343.4% - EBIT margin
-
-0.0% Much better than peer group: -5,913.1% - EBT margin
-
-1.0% Much better than peer group: -6,452.4% - Net margin
-
-2.3% Much better than peer group: -5,761.4% - ROE
-
-4.3% Much better than peer group: -117.5% - ROA
-
-1.6% Much better than peer group: -394.8% - Asset turnover
-
67.4% Much better than peer group: 11.3% - FCF margin
-
-17.8% Much better than peer group: -4,713.6% - FCF yield
-26.3% - Efficiency ratio
98.2% - Net sales per employee
-
€1.54M - Net income per employee
-
-€36.03K